Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis.
Hematology (Amsterdam, Netherlands)（2023）
Abstract
There was no difference between pegfilgrastim and filgrastim for the rate of FN. The use of pegfilgrastim was still associated with rates of FN, grade 4 FN, severe neutropenia, and treatment delays due to FN in pediatric cancer patients.
MoreTranslated text
Key words
Granulocyte colony-stimulating factor,adolescents,cancer treatment,children,febrile neutropenia,meta-analysis,neutropenia,treatment delay
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined